1 Maldivian Rufiyaa = 0.052 British Pound Sterling

1 Maldivian Rufiyaa = 1.0039 Egyptian Pound

1 Malaysian Ringgit = 349.0415 Lebanese Pound

1 Malaysian Ringgit = 0.186 British Pound Sterling

1 Malaysian Ringgit = 3.591 Egyptian Pound

1 Nicaraguan Cordoba Oro = 43.9709 Lebanese Pound

1 Nicaraguan Cordoba Oro = 0.0234 British Pound Sterling

1 Nicaraguan Cordoba Oro = 0.4524 Egyptian Pound

1 Netherlands Antillean Guilder = 842.6693 Lebanese Pound

1 Netherlands Antillean Guilder = 0.449 British Pound Sterling

1 Netherlands Antillean Guilder = 8.6696 Egyptian Pound

1 Estonian Kroon = 106.066 Lebanese Pound

1 Estonian Kroon = 0.0565 British Pound Sterling

1 Estonian Kroon = 1.0912 Egyptian Pound

1 Danish Krone = 219.8491 Lebanese Pound

1 Danish Krone = 0.1171 British Pound Sterling

1 Danish Krone = 2.2619 Egyptian Pound

1 Fiji Dollar = 671.4306 Lebanese Pound

1 Fiji Dollar = 0.3578 British Pound Sterling

1 Fiji Dollar = 6.9078 Egyptian Pound

1 New Zealand Dollar = 928.5293 Lebanese Pound

1 New Zealand Dollar = 0.4948 British Pound Sterling

1 New Zealand Dollar = 9.5529 Egyptian Pound

1 Croatian Kuna = 218.0212 Lebanese Pound

1 Croatian Kuna = 0.1162 British Pound Sterling

1 Croatian Kuna = 2.243 Egyptian Pound

1 Peruvian Nuevo Sol = 445.0551 Lebanese Pound

1 Peruvian Nuevo Sol = 0.2371 British Pound Sterling

1 Peruvian Nuevo Sol = 4.5788 Egyptian Pound

1 Dominican Peso = 27.4845 Lebanese Pound

1 Dominican Peso = 0.0146 British Pound Sterling

1 Dominican Peso = 0.2828 Egyptian Pound

1 Papua New Guinean Kina = 440.989 Lebanese Pound

1 Papua New Guinean Kina = 0.235 British Pound Sterling

1 Papua New Guinean Kina = 4.537 Egyptian Pound

1 Brunei Dollar = 1070.4046 Lebanese Pound

1 Brunei Dollar = 0.5704 British Pound Sterling

1 Brunei Dollar = 11.0126 Egyptian Pound

Prime Minister David Cameron urged the European Commission to reject calls for a renewable energy target, saying such a plan may cost U.K. consumers 9 billion pounds ($14.8 billion) a year by 2030.

The Rivers State Government has asked it's Attorney-General and Commissioner for Justice to auction all vehicles that were impounded for violating the state’s lockdown directive.

Paulinus Nsirim, the state's Commissioner for Information and Communications, in a statement on Thursday, said interested Nigerians should check selected Nigerian newspapers in order to place their bids.

The statement reads, “Government will deal decisively with the residents of these areas if they are found to default again. 

“Anyone parading exemption letters except the one issued by the governor is doing so at his or her own risk as such permits are invalid.

“The Attorney-General and Commissioner for Justice has been directed to auction all vehicles that violated the lockdown order.

“Members of the public who are interested to buy the auctioned vehicles are to watch out for details in The Sun, The Nation and Vanguard Newspapers.”

(MENAFN - CDN Newswire) A recent comprehensive study titled [To enable links in your articles, contact MENAFN Click here ] starts with offering the ... ......

Title: Doctors Remove 132-Pound Tumor From Woman
Category: Health News
Created: 5/4/2018 12:00:00 AM
Last Editorial Review: 5/4/2018 12:00:00 AM

ABSTRACT

Iron is a vital mineral for almost all living organisms and has a pivotal role in central metabolism. Despite its great abundance on earth, the accessibility for microorganisms is often limited, because poorly soluble ferric iron (Fe³⁺) is the predominant oxidation state in an aerobic environment. Hence, the reduction of Fe³⁺ is of essential importance to meet the cellular demand of ferrous iron (Fe²⁺) but might become detrimental as excessive amounts of intracellular Fe²⁺ tend to undergo the cytotoxic Fenton reaction in the presence of hydrogen peroxide. We demonstrate that the complex formation rate of Fe³⁺ and phenolic compounds like protocatechuic acid was increased by 46% in the presence of HCO₃^– and thus accelerated the subsequent redox reaction, yielding reduced Fe²⁺. Consequently, elevated CO₂/HCO₃^– levels increased the intracellular Fe²⁺ availability, which resulted in at least 50% higher biomass-specific fluorescence of a DtxR-based Corynebacterium glutamicum reporter strain, and stimulated growth. Since the increased Fe²⁺ availability was attributed to the interaction of HCO₃^– and chemical iron reduction, the abiotic effect postulated in this study is of general relevance in geochemical and biological environments.

IMPORTANCE In an oxygenic environment, poorly soluble Fe³⁺ must be reduced to meet the cellular Fe²⁺ demand. This study demonstrates that elevated CO₂/HCO₃^– levels accelerate chemical Fe³⁺ reduction through phenolic compounds, thus increasing intracellular Fe²⁺ availability. A number of biological environments are characterized by the presence of phenolic compounds and elevated HCO₃^– levels and include soil habitats and the human body. Fe²⁺ availability is of particular interest in the latter, as it controls the infectiousness of pathogens. Since the effect postulated here is abiotic, it generally affects the Fe²⁺ distribution in nature.

The plasmas of diabetic or uremic patients and of those receiving peritoneal dialysis treatment have increased levels of the glucose-derived dicarbonyl metabolites like methylglyoxal (MGO), glyoxal (GO), and 3-deoxyglucosone (3-DG). The elevated dicarbonyl levels can contribute to the development of painful neuropathies. Here, we used stimulated immunoreactive Calcitonin Gene–Related Peptide (iCGRP) release as a measure of nociceptor activation, and we found that each dicarbonyl metabolite induces a concentration-, TRPA1-, and Ca2+-dependent iCGRP release. MGO, GO, and 3-DG were about equally potent in the millimolar range. We hypothesized that another dicarbonyl, 3,4-dideoxyglucosone-3-ene (3,4-DGE), which is present in peritoneal dialysis (PD) solutions after heat sterilization, activates nociceptors. We also showed that at body temperatures 3,4-DGE is formed from 3-DG and that concentrations of 3,4-DGE in the micromolar range effectively induced iCGRP release from isolated murine skin. In a novel preparation of the isolated parietal peritoneum PD fluid or 3,4-DGE alone, at concentrations found in PD solutions, stimulated iCGRP release. We also tested whether inflammatory tissue conditions synergize with dicarbonyls to induce iCGRP release from isolated skin. Application of MGO together with bradykinin or prostaglandin E2 resulted in an overadditive effect on iCGRP release, whereas MGO applied at a pH of 5.2 resulted in reduced release, probably due to an MGO-mediated inhibition of transient receptor potential (TRP) V1 receptors. These results indicate that several reactive dicarbonyls activate nociceptors and potentiate inflammatory mediators. Our findings underline the roles of dicarbonyls and TRPA1 receptors in causing pain during diabetes or renal disease.

The microtubule-binding taxanes, docetaxel and cabazitaxel, are administered intravenously for the treatment of castration-resistant prostate cancer (CRPC) as the oral administration of these drugs is largely hampered by their low and highly variable bioavailabilities. Using a simple, rapid, and environmentally friendly microwave-assisted protocol, we have synthesized a number of 3,5-bis(styryl)pyrazoles 2a-l, thus allowing for their screening for antiproliferative activity in the androgen-independent PC3 prostate cancer cell line. Surprisingly, two of these structurally simple 3,5-bis(styryl)pyrazoles (2a and 2l) had concentrations which gave 50% of the maximal inhibition of cell proliferation (GI₅₀) in the low micromolar range in the PC3 cell line and were thus selected for extensive further biologic evaluation (apoptosis and cell cycle analysis, and effects on tubulin and microtubules). Our findings from these studies show that 3,5-bis[(1E)-2(2,6-dichlorophenyl)ethenyl]-1H-pyrazole 2l 1) caused significant effects on the cell cycle in PC3 cells, with the vast majority of treated cells in the G₂/M phase (89%); 2) induces cell death in PC3 cells even after the removal of the compound; 3) binds to tubulin [dissociation constant (K_d) 0.4 ± 0.1 μM] and inhibits tubulin polymerization in vitro; 4) had no effect upon the polymerization of the bacterial cell division protein FtsZ (a homolog of tubulin); 5) is competitive with paclitaxel for binding to tubulin but not with vinblastine, crocin, or colchicine; and 6) leads to microtubule depolymerization in PC3 cells. Taken together, these results suggest that 3,5-bis(styryl)pyrazoles warrant further investigation as lead compounds for the treatment of CRPC.

Balamuthia mandrillaris is an under-reported, pathogenic free-living amoeba that causes Balamuthia amoebic encephalitis (BAE) and cutaneous skin infections. Although cutaneous infections are not typically lethal, BAE with or without cutaneous involvement is usually fatal. This is due to the lack of drugs that are both efficacious and can cross the blood-brain barrier. We aimed to discover new leads for drug discovery by screening the open-source Medicines for Malaria Venture (MMV) Malaria Box and MMV Pathogen Box, with 800 compounds total. From an initial single point screen at 1 and 10 μM, we identified 54 hits that significantly inhibited the growth of B. mandrillaris in vitro. Hits were reconfirmed in quantitative dose-response assays and 23 compounds (42.6%) were confirmed with activity greater than miltefosine, the current standard of care.

Currently, the expansion of the novel human respiratory coronavirus (known as SARS-CoV-2 [severe acute respiratory syndrome coronavirus 2], COVID-2019 [coronavirus disease 2019], or 2019-nCoV [2019 novel coronavirus]) has stressed the need for therapeutic alternatives to alleviate and stop this new epidemic. The previous epidemics of infections by high-morbidity human coronaviruses, such as SARS-CoV in 2003 and the Middle East respiratory syndrome coronavirus (MERS-CoV) in 2012, prompted the characterization of compounds that could be potentially active against the currently emerging novel coronavirus, SARS-CoV-2. The most promising compound is remdesivir (GS-5734), a nucleotide analog prodrug currently in clinical trials for treating Ebola virus infections. Remdesivir inhibited the replication of SARS-CoV and MERS-CoV in tissue cultures, and it displayed efficacy in nonhuman animal models. In addition, a combination of the human immunodeficiency virus type 1 (HIV-1) protease inhibitors lopinavir/ritonavir and interferon beta (LPV/RTV–IFN-β) was shown to be effective in patients infected with SARS-CoV. LPV/RTV–IFN-β also improved clinical parameters in marmosets and mice infected with MERS-CoV. Remarkably, the therapeutic efficacy of remdesivir appeared to be superior to that of LPV/RTV–IFN-β against MERS-CoV in a transgenic humanized mouse model. The relatively high mortality rates associated with these three novel human coronavirus infections, SARS-CoV, MERS-CoV, and SARS-CoV-2, have suggested that proinflammatory responses might play a role in the pathogenesis. It remains unknown whether the generated inflammatory state should be targeted. Therapeutics that target the coronavirus alone might not be able to reverse highly pathogenic infections. This minireview aims to provide a summary of therapeutic compounds that have shown potential in fighting SARS-CoV-2 infections.